Celera, Abbott Shift From Profit-Sharing Alliance to Distribution and Royalty Agreements | GenomeWeb

NEW YORK (GenomeWeb News) – Celera Corporation and Abbott announced today that they have revised their strategic alliance agreement, moving from a profit-sharing deal to new worldwide distribution and royalty agreements.

Under one of these agreements, Abbott will have the right to exclusively distribute certain Celera-manufactured molecular diagnostic products. A second agreement gives Celera royalties on sales of m2000 real-time PCR system reagents, instruments, services, and related consumables.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.